Alembic Pharmaceuticals Reaches 242 USFDA ANDA Approvals

Alembic Pharmaceuticals Limited has reached 242 cumulative US Food and Drug Administration ANDA approvals, comprising 222 final approvals and 20 tentative approvals. The total reflects continued additions to its US generics pipeline, including recent approvals for products addressing ear infections, constipation, eye conditions and other treatments.

What has Alembic Pharmaceuticals received from the USFDA?

Alembic Pharmaceuticals has accumulated 242 approvals for Abbreviated New Drug Applications, or ANDAs, from the US Food and Drug Administration. Of this total, 222 are final approvals and 20 are tentative approvals, according to the company information provided.

Final approval allows an ANDA applicant to market the approved generic product in the United States, subject to the applicable requirements. Tentative approval means the USFDA has completed its scientific review but final marketing clearance remains dependent on the resolution of factors such as patents or exclusivity for the reference product.

The company has continued to file ANDAs with the regulator and receive multiple final approvals. Its 2026 milestones include five ANDA approvals in one month, a development that added to the US generics portfolio.

On October 27, 2026, Alembic Pharmaceuticals announced final USFDA approval for Valganciclovir for Oral Solution, 50 mg/mL. Earlier in the same month, it reported final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP 0.3%/0.1%.

Which generic medicines have recently received approval?

Alembic Pharmaceuticals has received approvals across several therapeutic categories, covering ear infections, eye conditions, acne, constipation and other treatments. The Ciprofloxacin and Dexamethasone Otic Suspension is indicated for certain ear infections in paediatric patients aged six months and above, as well as adults and elderly patients.

The approved otic suspension ANDA is therapeutically equivalent to Ciprodex Otic Suspension 0.3%/0.1% of Sandoz Inc. The company also received final approval for Prucalopride Tablets, 1 mg and 2 mg, which are indicated for chronic idiopathic constipation in adults and are therapeutically equivalent to Takeda Pharmaceuticals USA Inc's Motegrity Tablets.

Other disclosed approvals include Dapsone Gel 5% for topical treatment of acne vulgaris, Oseltamivir Phosphate for Oral Suspension 6 mg/mL, and Difluprednate ophthalmic emulsion 0.05% for eye inflammation and pain following surgery. Alembic Pharmaceuticals has also reported approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension 0.5%/0.3% in 5 mL and 10 mL presentations for eye infections.

The company has additionally disclosed USFDA approvals relating to Tretinoin Cream USP 0.025%, Paroxetine ER Tablets, Ticagrelor Tablets 60 mg and a generic version of Stalevo for Parkinson's treatment. These approvals indicate that its US filing programme spans multiple dosage forms and therapy areas.

What does the Binimetinib tentative approval mean?

Alembic Pharmaceuticals has received tentative approval for Binimetinib Tablets 45 mg, a kinase inhibitor used with encorafenib in specified melanoma and non-small cell lung cancer settings. It had previously received tentative approval for Binimetinib Tablets 15 mg.

The 45 mg product is a generic version of Array's Mektovi. The company stated that the US market for the product was estimated at $259 million for the 12 months ended March 2026.

Alembic Pharmaceuticals is the sole first applicant with a Paragraph IV certification for the 45 mg product, according to the information provided. This position qualifies it for 180 days of generic marketing exclusivity once final approval is granted.

Tentative approval does not by itself permit commercial marketing. The timing of a launch will depend on the company obtaining final approval and on any relevant patent or exclusivity conditions associated with the reference product.

How is Alembic Pharmaceuticals supporting its US business?

Alembic Pharmaceuticals derives its largest revenue segment from export sales of generic formulations to the United States and Europe. Its USFDA- and EU GMP-approved facilities support this export-focused formulation business.

Regulatory approvals are central to the operating model because an approved ANDA creates the basis for supplying a generic medicine in the US market. The number and range of approvals therefore provide a measure of the company's available product pipeline, though an approval alone does not establish sales, launch timing or profitability.

The company also reported a USFDA inspection of its Vadodara bioequivalence facility conducted from August 31 to September 10, 2026. The inspection concluded with nil observations, as disclosed by Alembic Pharmaceuticals.

A clean inspection outcome is relevant for a company that relies on regulated export markets and continued product filings. It indicates that the disclosed inspection ended without observations, while the information provided does not quantify any direct financial effect from the inspection.

What are the key disclosed USFDA developments?

Alembic Pharmaceuticals' recent regulatory updates show a combination of final approvals, tentative approvals and facility compliance activity. The following table summarises the principal facts disclosed in the available information.

For investors and industry participants, the disclosures underline the importance of the US market to Alembic Pharmaceuticals' generic formulations business. The company has not provided figures in the supplied material on revenue from individual products, commercial launch dates, market share or the financial contribution of these approvals.

The approval flow also reflects the role of USFDA review in the Indian pharmaceutical export sector. Manufacturers need both a viable filing pipeline and compliant facilities to participate in regulated markets, while actual product sales remain subject to competitive conditions and the timing of launches.

Conclusion

Alembic Pharmaceuticals has built a disclosed USFDA approval base of 242 cumulative ANDAs, with 222 final approvals and 20 tentative approvals. Its latest regulatory updates cover products across several treatment categories and support the company's export-led generic formulations model in the United States and Europe.

The next disclosed item to watch is the potential final approval of Binimetinib Tablets, for which Alembic Pharmaceuticals holds tentative approval and sole first-applicant status with a Paragraph IV certification. The company will also continue filing ANDAs and seeking final approvals as it develops its US generics portfolio.